ArticleOncotarget2016

Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.

Junjie Piao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.